Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia

Cancer Epidemiology

Volumn 35, Issue 5, 2011, Pages 465-470

  Alibegashvili, Tamar ^a   Clifford, Gary M ^b   Vaccarella, Salvatore ^b   Baidoshvili, Alexi ^c   Gogiashvili, Liana ^a   Tsagareli, Zurab ^a   Kureli, Ioseb ^a   Snijders, Peter J F ^c   Heideman, Daniëlle A M ^c   van Kemenade, Folkert J ^c   Meijer, Chris J L M ^c   Kordzaia, Dimitri ^a   Franceschi, Silvia ^b  

^a Alexandre Natishvili Institute of Morphology   (Georgia)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Georgia; Human papillomavirus; Prevalence

Indexed keywords

VIRUS DNA;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; ARTICLE; FEMALE; GEORGIA (REPUBLIC); GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 82; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GEORGIA; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 80052937990     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.12.006     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010. Lyon, France, International Agency for Research on Cancer. Available from: http://globocan.iarc.fr/.
2. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009, 45:2640-2648.
3. Arbyn M., Antoine J., Magi M., Smailyte G., Stengrevics A., Suteu O., et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer 2010, June 21. [Epub ahead of print].
4. Levi F., Lucchini F., Negri E., Franceschi S., la Vecchia C. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000, 36:2266-2271.
5. Maucort-Boulch D., Franceschi S., Plummer M. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008, 17:717-720.
6. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
7. Wright T.C., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287:2120-2129.
8. Bulk S., van Kemenade F.J., Rozendaal L., Meijer C.J. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004, 57:388-393.
9. Jacobs M.V., Walboomers J.M., Snijders P.J., Voorhorst F.J., Verheijen R.H., Fransen-Daalmeijer N., et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000, 87:221-227.
10. van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787.
11. Muňoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
12. Doll R., Payne P., Waterhouse J. Cancer incidence in five continents: a technical report 1966, Springer-Verlag, Berlin, [for UICC].
13. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
14. Curado M.P., Edwards B., Shin H.R., Storm H., Ferlay J., Heanue M., et al. Cancer incidence in five continents 2007, vol. IX. IARC Scientific Publication No. 160. [IX], Lyon, IARC.
15. De Vuyst H., Clifford G., Li N., Franceschi S. HPV infection in Europe. Eur J Cancer 2009, 45:2632-2639.
16. Bardin A., Vaccarella S., Clifford G.M., Lissowska J., Rekosz M., Bobkiewicz P., et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer 2008, 44:557-564.
17. Ronco G., Ghisetti V., Segnan N., Snijders P.J., Gillio-Tos A., Meijer C.J., et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005, 41:297-305.
18. Franceschi S., Herrero R., Clifford G.M., Snijders P.J., Arslan A., Anh P.T., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119:2677-2684.
19. De Vuyst H., Gichangi P.B., Estambale B., Njuguna E., Franceschi S., Temmerman M. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer 2008, 122:244-246.
20. Giuliano A.R., Papenfuss M., Abrahamsen M., Denman C., de Zapien J.G., Henze J.L., et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 2001, 10:1129-1136.
21. Vaccarella S., Franceschi S., Herrero R., Muñoz N., Snijders P.J., Clifford G.M., et al. Sexual behavior, condom use and human papillomavirus: pooled analysis of the International Agency for Research on Cancer human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006, 15:326-333.
22. Vaccarella S., Herrero R., Dai M., Snijders P.J., Meijer C.J., Thomas J.O., et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006, 15:2148-2153.
23. Vaccarella S., Herrero R., Snijders P.J., Dai M., Thomas J.O., Hieu N.T., et al. Smoking and human papillomavirus infection: pooled analysis of the international agency for research on cancer HPV prevalence surveys. Int J Epidemiol 2008, 37:536-546.
24. Giuliano A.R., Sedjo R.L., Roe D.J., Harri R., Baldwi S., Papenfuss M.R., et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002, 13:839-846.
25. Li N., Franceschi S., Howell-Jones R., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128(4):927-935.
26. Franceschi S., Plummer M., Clifford G., de Sanjose S., Bosch X., Herrero R., et al. Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 2009, 101:865-870.
27. Denny L., Quinn M., Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine 2006, 24(Suppl. 3). S3-71-S3/77.
28. Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
29. Bulkmans N., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
30. Arbyn M., Ronco G., Meijer C.J., Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009, 10:935-936.
31. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
32. The GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.